AripiprazoleIt is a quinoline derivative is a new antipsychotic agent with a unique pharmacological profile in that it is a partial agonist at the D2 and 5-HT1A receptor sites and an antagonist at the 5-HT2A receptor site.
Schizophrenia- acute treatment, Schizophrenia-chronic treatment, Acute mania.
The recommended starting and target dose for aripiprazole is 10 or 15 mg/day administered on a once-a-day schedule without regard to meals. Dosage increases should not be made before 2 weeks, the time needed to achieve steady state. At least 1 to 2 weeks, and sometimes up to 4 weeks, may pass before aripiprazole reaches its full effects.
Aripiprazole should be used with caution in patients with known cardiovascular diseases (history of myocardial infarction or ischemic heart disease, heart failure or conduction abnormalities, cerebrovascular diseases, or conditions, which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications), Alzheimer's disease, and dementia.
Headache, insomnia, somnolence, dyspepsia, constipation, pain, nausea, vomiting, asthenia, dizziness, abdominal pain, dry mouth, anxiety, akathisia, orthostatic, hypotension, hypertonia, tremor, blurred vision.
|Brand Name||Manufactured by|
|APICORD||CONCORD DRUGS LTD.|
|APRIZOL||SAIN MEDICAMENT PVT. LTD.|
|ARIA||NICHOLAS PIRAMAL INDIA|
|ARILAM||SHB ASIA LIMITED|
|ARILAN||MICRO LABS LIMITED|
|ARIP MT||TORRENT LABS (P) LTD.|
|ARIPAT MD||GENTECH HEALTHCARE PVT. LTD.|
|ARIPICON||CONSERN PHARMA (P) LTD.|
|ARIPION||RELIANCE LIFECARE PVT LTD|
|ARISUN||SUNRISE REMEDIES PVT. LTD|
|ARIZA`||MARC LABORATORIES PVT. LTD|
|ARPIZOL||Sun Pharmaceutical Industries Ltd.|
|ARZODEL||DELLWICH HEALTHCARE LLP|
|ASPRITO||INTAS PHARMACEUTICALS LTD.|
|ELRIP||ELITE PHARMA PVT. LTD.|